Healthtech Solutions Inc. (HLTT)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Healthtech Solutions Inc. (HLTT) with AI Score 56/100 (Hold). Healthtech Solutions Inc. focuses on developing wound care products and AI-based image analysis software. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Healthtech Solutions Inc. (HLTT) Healthcare & Pipeline Overview
Healthtech Solutions Inc. is a life sciences company developing wound care products like AmnioBind and AI-driven imaging software for musculoskeletal and cardiac applications. Operating in the healthcare information services sector, the company aims to improve treatment outcomes through innovative technologies, but faces challenges inherent to OTC-listed, early-stage ventures.
Investment Thesis
Healthtech Solutions Inc. presents a high-risk, high-reward investment opportunity. The company's focus on innovative wound care and AI-driven diagnostics addresses significant market needs. AmnioBind, if successfully commercialized, could capture a share of the growing wound care market. The AI-based imaging software offers potential for improved diagnostic accuracy and efficiency. However, the company's OTC listing, negative profitability (Profit Margin: -180.3%), and small market capitalization ($0.00B) indicate substantial risks. Key catalysts include successful clinical trials, regulatory approvals, and strategic partnerships. The investment thesis hinges on the company's ability to navigate the regulatory landscape and secure funding to support its development programs. The high Beta of 1.95 suggests high volatility.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross Margin of 92.7% indicates strong potential profitability if sales volume increases.
- Focus on AmnioBind, a placental membrane allograft, targets a growing market for advanced wound care.
- Development of AI-based image analysis software positions the company in the rapidly expanding field of medical imaging.
- Based in the US, allowing for direct access to one of the largest healthcare markets.
- Operating with a small team of 18 employees, indicating a lean operational structure.
Competitors & Peers
Strengths
- Innovative wound care technology (AmnioBind).
- AI-based image analysis software development.
- Focus on regenerative medicine.
- Potential for novel cardiac treatment technology.
Weaknesses
- OTC listing indicates higher risk.
- Negative profitability and small market capitalization.
- Limited operating history.
- Dependence on regulatory approvals.
Catalysts
- Upcoming: Clinical trial results for AmnioBind in treating diabetic foot ulcers.
- Upcoming: Regulatory approvals for AI-based image analysis software.
- Ongoing: Strategic partnerships with hospitals and clinics.
- Ongoing: Expansion into new wound care applications.
- Ongoing: Development of the curative waveform technology for heart rhythm correction.
Risks
- Potential: Competition from established medical device companies.
- Potential: Regulatory hurdles and delays.
- Ongoing: Funding constraints and dependence on securing additional capital.
- Potential: Technological obsolescence.
- Ongoing: OTC listing indicates higher risk and limited liquidity.
Growth Opportunities
- Expansion of AmnioBind into new wound care applications: The market for advanced wound care products is estimated to reach billions of dollars globally. Healthtech Solutions can expand AmnioBind's application to treat various types of chronic wounds, including pressure ulcers and surgical wounds. This expansion requires further clinical trials and regulatory approvals, but could significantly increase the product's market potential. Timeline: Ongoing.
- Development and commercialization of AI-based diagnostic tools: The market for AI in healthcare is projected to experience substantial growth in the coming years. Healthtech Solutions can capitalize on this trend by developing and commercializing its AI-based image analysis software for chest and musculoskeletal systems. This requires further development, validation, and regulatory clearance. Timeline: 2-3 years.
- Strategic partnerships with hospitals and clinics: Collaborating with healthcare providers can accelerate the adoption of Healthtech Solutions' products and technologies. Partnerships can provide access to patient populations, clinical data, and distribution channels. These partnerships can also facilitate the integration of the company's solutions into existing healthcare workflows. Timeline: Ongoing.
- Geographic expansion into international markets: The global market for wound care and diagnostic imaging is vast. Healthtech Solutions can expand its reach by entering international markets, such as Europe and Asia. This requires adapting its products and technologies to meet local regulatory requirements and market needs. Timeline: 3-5 years.
- Development of the curative waveform technology for heart rhythm correction: The company's software technology that compares a healthy heart rhythm electronic signal with a damaged heart's signal to derive an electronic signal representing the curative waveform has the potential to revolutionize cardiac treatment. Further research, development, and clinical trials are needed to validate this technology. Timeline: 5+ years.
Opportunities
- Expansion into new wound care applications.
- Commercialization of AI-based diagnostic tools.
- Strategic partnerships with healthcare providers.
- Geographic expansion into international markets.
Threats
- Competition from established medical device companies.
- Regulatory hurdles and delays.
- Funding constraints.
- Technological obsolescence.
Competitive Advantages
- Proprietary AmnioBind technology with potential for strong efficacy in wound healing.
- AI-based image analysis software offering improved diagnostic accuracy.
- Focus on innovative solutions in regenerative medicine and medical imaging.
- Potential for patent protection on key technologies.
About HLTT
Founded in 2018 and based in Tuckahoe, New York, Healthtech Solutions Inc. operates as a life sciences company focused on developing and commercializing innovative healthcare solutions. The company's primary focus is on wound care products, particularly for acute and chronic wounds. Their lead product, AmnioBind, is a placental membrane allograft designed to treat burns and non-healing wounds, such as diabetic foot ulcers. This technology leverages the regenerative properties of placental tissue to promote faster and more effective wound healing. In addition to wound care, Healthtech Solutions is developing ultrasound imaging and artificial intelligence-based image analysis software. These technologies are intended for use in the treatment of chest and musculoskeletal systems, enabling more accurate and efficient diagnoses. The company is also working on software technology that analyzes heart rhythm electronic signals to derive a curative waveform, potentially offering a novel approach to cardiac treatment. Healthtech Solutions operates through its subsidiaries, managing all aspects of product development, manufacturing, and commercialization. As a relatively young company, it is still in the early stages of market penetration and faces the challenges of establishing its brand and securing regulatory approvals. The company's small size, with 18 employees, reflects its current stage of development and its focus on research and development activities.
What They Do
- Develops AmnioBind, a placental membrane allograft for treating burns and non-healing wounds.
- Creates ultrasound imaging software for chest and musculoskeletal system applications.
- Develops AI-based image analysis software to aid in medical diagnoses.
- Researches software technology to derive a curative waveform for heart rhythm correction.
- Focuses on regenerative medicine and advanced diagnostic technologies.
- Operates through subsidiaries to manage product development and commercialization.
Business Model
- Develops and commercializes wound care products.
- Licenses or sells AI-based diagnostic software.
- Generates revenue through product sales and licensing agreements.
- Focuses on innovation in regenerative medicine and medical imaging.
Industry Context
Healthtech Solutions operates within the healthcare information services and medical devices industry, a sector characterized by rapid innovation and increasing demand for advanced technologies. The wound care market is driven by the rising prevalence of chronic diseases such as diabetes, which leads to non-healing ulcers. The market for AI-based diagnostic tools is also expanding rapidly, fueled by the need for more accurate and efficient diagnostic methods. Competition includes established medical device companies and emerging biotech firms. Healthtech Solutions aims to differentiate itself through its focus on placental-derived therapies and AI-driven solutions.
Key Customers
- Hospitals and clinics using wound care products.
- Medical professionals treating chronic wounds.
- Radiologists and imaging specialists.
- Healthcare providers seeking advanced diagnostic tools.
Financials
Chart & Info
Healthtech Solutions Inc. (HLTT) stock price: Price data unavailable
Latest News
No recent news available for HLTT.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HLTT.
Price Targets
Wall Street price target analysis for HLTT.
MoonshotScore
What does this score mean?
The MoonshotScore rates HLTT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: James Pesoli
CEO
James Pesoli serves as the CEO of Healthtech Solutions Inc., leading a team of 18 employees. Information regarding his detailed career history, educational background, and previous roles is not available. His leadership is focused on guiding the company's strategic direction and overseeing the development and commercialization of its healthcare technologies.
Track Record: Due to limited information, it is difficult to assess James Pesoli's specific achievements and strategic decisions at Healthtech Solutions Inc. However, as CEO since 2018, he has overseen the company's efforts to develop AmnioBind and AI-based diagnostic tools.
HLTT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Healthtech Solutions Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility compared to listed securities.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in Healthtech Solutions Inc.
- Lower liquidity can lead to price volatility and difficulty in executing trades.
- OTC listing may indicate a higher risk of fraud or mismanagement.
- The company may not meet the listing requirements of major exchanges.
- Dependence on securing additional funding to support operations.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the market potential for the company's products and technologies.
- Evaluate the company's competitive position within the industry.
- Determine the company's cash runway and funding needs.
- Consult with a qualified financial advisor before investing.
- Understand the risks associated with investing in OTC-listed stocks.
- Development of innovative wound care technology (AmnioBind).
- Focus on AI-based diagnostic software.
- Presence in the healthcare sector, which is subject to regulatory oversight.
- Company has been in operation since 2018.
- Management team is actively working to develop and commercialize products.
Common Questions About HLTT
What does Healthtech Solutions Inc. do?
Healthtech Solutions Inc. is a life sciences company focused on developing and commercializing innovative healthcare solutions. Their primary focus is on wound care products, particularly AmnioBind, a placental membrane allograft designed to treat burns and chronic wounds like diabetic foot ulcers. Additionally, they are developing AI-based image analysis software for diagnostic applications and exploring novel cardiac treatment technologies. The company aims to improve patient outcomes through advanced technologies in regenerative medicine and medical imaging.
What do analysts say about HLTT stock?
Currently, there is no available analyst coverage for Healthtech Solutions Inc. due to its OTC listing and small market capitalization. Therefore, no consensus estimates or price targets are available. Investors should conduct their own thorough research and due diligence before making any investment decisions, considering the inherent risks associated with OTC-listed companies and the lack of analyst opinions.
What are the main risks for HLTT?
The main risks for Healthtech Solutions Inc. include its OTC listing, which indicates higher risk and limited liquidity. The company's negative profitability and small market capitalization also pose financial challenges. Regulatory hurdles and competition from established medical device companies are additional concerns. Furthermore, the company's dependence on securing additional funding and the potential for technological obsolescence represent significant risks to its long-term success.
What are the key factors to evaluate for HLTT?
Healthtech Solutions Inc. (HLTT) currently holds an AI score of 56/100, indicating moderate score. Key strength: Innovative wound care technology (AmnioBind).. Primary risk to monitor: Potential: Competition from established medical device companies.. This is not financial advice.
How frequently does HLTT data refresh on this page?
HLTT prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HLTT's recent stock price performance?
Recent price movement in Healthtech Solutions Inc. (HLTT) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative wound care technology (AmnioBind).. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HLTT overvalued or undervalued right now?
Determining whether Healthtech Solutions Inc. (HLTT) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HLTT?
Before investing in Healthtech Solutions Inc. (HLTT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company due to its OTC listing and small market capitalization.
- Financial data is based on available information and may not be comprehensive.
- AI analysis is pending and may provide further insights in the future.